Neuroprotective role of erythropoietin in neonates

J Matern Fetal Neonatal Med. 2012 Oct;25 Suppl 4:105-7. doi: 10.3109/14767058.2012.715025.

Abstract

This review summarizes target populations of neonates for which erythropoietin (Epo) neuroprotective therapy might be of benefit, and the mechanisms by which Epo functions as a neuroprotective agent. Potential risks of Epo are reviewed. Finally, the progression of Epo neuroprotection from preclinical studies to translational studies is discussed.

Publication types

  • Evaluation Study
  • Review

MeSH terms

  • Brain / drug effects
  • Brain / metabolism
  • Erythropoietin / administration & dosage
  • Erythropoietin / metabolism
  • Erythropoietin / physiology*
  • Erythropoietin / therapeutic use
  • Humans
  • Hypoxia-Ischemia, Brain / etiology
  • Hypoxia-Ischemia, Brain / prevention & control
  • Infant, Newborn / metabolism*
  • Infant, Newborn, Diseases / etiology
  • Infant, Newborn, Diseases / prevention & control
  • Infant, Premature, Diseases / etiology
  • Infant, Premature, Diseases / prevention & control
  • Nervous System Diseases / etiology
  • Nervous System Diseases / prevention & control
  • Neuroprotective Agents* / administration & dosage
  • Neuroprotective Agents* / adverse effects
  • Neuroprotective Agents* / metabolism
  • Neuroprotective Agents* / therapeutic use
  • Risk Factors

Substances

  • Neuroprotective Agents
  • Erythropoietin